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Abstract
Background: Fibrates are widely used hypolipidemic drugs, which serve as ligand of peroxisome proliferator-
activated receptor α (PPARα). Recently, they have also been considered as potential anticancer agents. We studied
effect of fibrates treatment on cell proliferation, expression of CYP2J2 and concomitant changes in expression of
cell cycle regulatory proteins in three different human cell lines: HEK293, HepG2, and HT-29.
Methods: We used WST-1 viability test, western blot and immunocytochemistry for detection of proteins of
interests and analysis of cell cycle.
Results: Our results showed that at lower concentrations of all tested fibrates, viability of all tested cell lines is
increased, whereas at higher concentrations, repression is apparent. Unfortunately, the viability of tested cells is
predominantly increased in a range of concentration which is reached in patient plasma. This phenomenon is
accompanyed by elevation of CYP2J2, increased number of cyclin E-positive cells and decreased number of Cdc25A-
positive cells in all tested cell lines, and elevated cyclin A expression in HepG2 and HT-29. These changes are
concentration-dependent. We suppose that increased level of CYP2J2 could explain enhanced cell proliferation in
lower concentration of fibrates.
Conclusion: Based on our results, we suggested there is no anti-cancer effect of fibrates in tested carcinoma
cell lines.
Keywords: Peroxisome proliferator-activated receptor α, Hypolipidemic drugs, Proliferation, CYP Epoxygenases,
Epoxyeicosatrienoic acids, Cancer
Background
Fibrates are well-known ligands of peroxisome proliferator-
activated receptor α (PPARα) which are clinically widely
used drugs for treatment of dislipidemias. PPARα is ligand-
activated transcription factor. After ligand binding, histon
deacetylase (HDAC) co-repressors are released and PPARs
heterodimerize with retinoid X receptor (RXR). After that,
RNA polymerase II and co-activators with histone acetyl
transferase (HAT) activity are recruited to this complex.
The complex binds to peroxisome proliferator response
elements (PPREs) in target genes and transcription of target
genes is increased. PPARs can lead to downregulation of
gene expression which occurs by interfering with other pro-
teins and transcription factors through a trans-repression
mechanism [1]. The transcriptional activity of PPARs can
be also affected by crosstalk between phosphorylation and
dephosphorylation [2].
PPARα is highly expressed in tissues with active fatty
acid metabolism, such as the liver, heart muscle, intes-
tine and kidney [3]. PPARα acts as lipid sensor and play
important role in regulation of nutrient metabolism and
energy homeostasis. Beside that, it is involved in regula-
tion of inflammation and xenobiotic metabolism [4].
PPARα is activated by various endogenous and exogen-
ous ligands, for example fatty acids, eicosanoids, phtalates,
etc. Recently, fibrates have been also considered as potential
anticancer agents with relatively low toxicity. Despite this
fact, the role of PPARα in cancerogenesis is controversial.
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There are a lot of studies describing their potential for
cancer treatment and chemoprevention [5–11]. On the
other hand, Suchanek et al. [12], descibed an increase in
proliferation in human breast carcinoma cell lines after
PPARα ligands treatment. Thus, the exact role of PPARα
and its ligands in cancer remains unclear. It has been de-
scribed a lot of effects of PPARα ligands on tumours cells
and tumours (see Additional file 1) [3, 4, 10, 13–16].
As mentioned above, PPARα plays a role in the regula-
tion of xenobiotic metabolism enzymes. Beside other
xenobiotic enzymes, PPARα plays role in regulation of
cytochrome P450 (CYPs) enzymes called CYP epoxy-
genases [4]. These enzymes, mainly CYP2C and CYP2J,
convert arachidonic acid to epoxieicosatrienoic acids
(EETs) which have generaly cytoprotective effects [16].
The main organs involved in the absorption, distribu-
tion, metabolism, and elimination of xenobiotics are
liver, intestines, and kidney. Therefore three different
human cell lines derived from these organs has been
used in this study: HEK293 (human embryonic kidney)
and two carcinoma-derivated cell lines HepG2 (hepato-
cellular carcinoma) and HT-29 (human colorectal adno-
carcinoma). We investigated the influence of fibrates on
viability of these cell lines and consequent changes in
expression of CYP2J2 and cycle regulatory proteins. Ac-
cording to our best knowledge, this is the first study
which demonstrate changes in CYP2J2 protein expres-




HEK293 and HepG2 cells were routinely cultured in
DMEM (HyClone, SH 30249.01). HT-29 cells were
cultured in RPMI-1640(Sigma Aldrich, R5866). Both
DMEM and RPMI media were supplemented with 10 %
FBS (HyClone, cat. no. SV30180.02) and penicilin (100
U/ml), streptomycin (100 mg/l). Cells were incubated at
37 °C and 5 % CO2. Cells were passaged twice per week.
All cell lines were obtained from the American Type
Culture Collection. The cell lines authentication via STR
profiles has been performed by Department of clinical
genetics, Palacky University, Olomouc.
Proliferation assay
We used 4 different PPARα ligands (fibrates): fenofibrate
(Cayman, cat. no. 10005368), bezafibrate (Cayman, cat. no.
10009145), gemfibrozil (Sigma-Aldrich, cat. no. G9518),
WY-14643 (Sigma-Aldrich, cat. no. C7081) to investigate
their effect on proliferation of HEK293, HepG2, and HT-
29 cell lines. Fenofibrate, bezafibrate, gemfibrozil, and WY-
14643 were solved in dimethyl sulfoxid to stock solution at
concentration 10 mM.
Cells were plated in 96-well plates at density of 5000
cells/ well for HEK293 and 10000 cells/well for HepG2
and HT-29 in growth medium. Cells were incubated
overnight and then different ligands of PPARα in differ-
ent concentrations were added. Final volume of the
growth media was 100 μl/well. Cells were incubated with
ligands for 72 h at 37 °C and 5 % CO2. Moreover, cells
were incubated in two different concentrations of
DMSO (0.1 and 1 %) to confirm that there is no signifi-
cant influence of DMSO on cell viability.
To quantify the cell viability, 10 μl of WST-1 re-
agent per well (Roche, cat. no. 11 644 807 001) was
added into the growth media. Cells were incubated
90 min at 37 °C and 5 % CO2 before the measure-
ment of absorbance at 450 nm with microplate reader
Power Wave XS (Bio-Tek).
Western blot analysis
HEK293, HepG2 and HT-29 cells were incubated for
72 h in presence of all tested fibrates in concentrations
with maximal viability and IC10 (obtained by WST-1
viability test, see Result section). Samples were separed by
SDS-PAGE in 10 % stacking gel. Then, proteins were
transfered to Amesham Hybond-ECL membrane (GE
Healthcare). Mouse monoclonal antibody against CYP2J2
(NBP2-01178, NovusBiologicals) was used. As endogen-
ous control, GAPDH expression was used. Detection was
performed with mouse monoclonal primary antibody
(DAKO). The incubation took overnight. Next day, mem-
branes were washed in PBS Tween 20 buffer and then in-
cubated with secondary antibody (7076, Cell Signalling)
for 1 h in room temperature and washed. Detection was
accomplished by SuperSignal West Femto Maximum
Sensitivity Substrate (34095, Thermo Scientific) and mem-
branes were exposed to Biomax Light Film (Kodak). The
films were scanned by densitometer GS-700 (BioRad).
Relative protein expression was evaluated by measur-
ing optical density (OD) by ImageJ software (National
Institute of Health, USA).
Immunocytochemistry
To confirm ratio of proliferating cells (by Ki-67) after
the treatment by clinically used fibrates (fenofibrate,
bezafibrate and gemfibrozil), presence and localization of
PPARα receptor and estimate changes in expression of
cell cycle regulators cyclin E, cyclin A, and Cdc25A in
control and fibrate-treated cell lines, we used two-step
immunocytochemical method. The same staining was
performed for comfirmation of p53 in tested cell lines.
These protein have been chosen based on our prelimin-
ary experiments (data not shown).
Cells were treated by those concentrations of
PPARα ligands in which WST-1 test showed maximal
viability (see Result section) for 72 h. Moreover, based
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on the results, cell lines were treated also IC10 for
detection of chosen antigens. Cells were seated in
concentration of 128 000 cells per 1 ml in drop of
media on the sterile slides. After cell adhesion (6 h
minimum) the fresh media was added and cells were
incubated overnight. Next day, cells were treated by
PPARα ligands in appropriate concentrations for 72 h.
As a control, the cells treated by 0.1 % DMSO were
used. Then, slides were washed by PBS buffer,fixed
for 10 min in cold methanol:aceton (1:1) solution, air-
dried and storage at −20 °C.
Ki-67 by mouse monoclonal antibody (DAKO,
N1633) at dilution 1:200, PPARα by rabbit polyclonal
antibody (Abcam, ab8934) at dilution 1:50, cyclin E
by mouse monoclonal antibody (Santa Cruz, sc-247)
at dilution 1:50, cyclin A by rabbit polyclonal anti-
body (Santa cruz, sc-751) at dilution 1:100, Cdc25A
by mouse monoclonal antibody (Santa Cruz, sc-
56264) were detected. The appropriate dilution of the
antibodies was specified by staining positive controls
recommended by manufacturers in datasheets. Anti-
bodies were diluted in Dako REAL™ Antibody Diluent
(DAKO). Western blot and immunocytochemistry
evaluation data for rabbit polyclonal antibodies are
provided by manufacturers.
Before staining, the samples were hydrated by tap
water wash for 5 min. To block endogenous peroxidase
activity, slides were incubated with 0.3 % H2O2 for
15 min. Then, heat antigen retrieval was performed. For
blocking non-specific background staining, the samples
were incubated with Protein Block (DAKO) for 10 min
at room temperature. The next step was an incuba-
tion of slides with primary antibodies for 1 h at room
temperature. The detection of proteins was performed
by EnVision™ Detection System, Peroxidase/DAB,
Rabbit/Mouse (DAKO). Tris buffer (pH 7.6) was used
for washing between different steps. Nuclei of all
samples were counterstained with hematoxylin and
washed in tap water. Then, samples were dehydrated
by passage through ethanol, aceton, and xylen washes
and coverslipped.
Data analysis
Results of proliferation assay (IC50, IC10 and concen-
tration with maximal viability) are shown in Table 1
as an average ± standard deviation (SD) (n = 3). Results
of cell viability assay were evaluated by Student’s t-test
at the p < 0.05 level of significance. All calculations
were performed using MS Excel 2010. Statistically
significant results are marked with asterisk (*).
Prior to evaluation of immunohistochemical samples,
the samples were coded to minimize observer bias.
Immunocytochemical samples stained for Ki-67, cyclin
E, cyclin A, and Cdc25A were evaluated as % of positive
cells in 3 different fields of vision, magn. 100×. The aver-
age % of positive cells were calculated for both, control
and treated cells. The evaluation of PPARα staining was
based on the fact that activation of the receptor leads to
incerased nuclear positivity. The samples were evaluated
as % of nuclear positive cells in 3 different fields of
vision, magn. 100×. The whole set of experiment was
performed three-times.
The results obtained for Ki-67, cyclin E, cyclin A, and
Cdc25A are shown as average % of positive cells ± SD
(n = 3). Moreover, the fold change for all treated
Table 1 Maximal viability concentration, IC10, and IC50 of fenofibrate, bezafibrate, and gemfibrozil in tested cell lines
PPARα ligand max. viability IC10 (μM) IC50 (μM)
concentration (μM) relative viability (% of control)
HEK293 fenofibtrate 1.2 ± 0.8 147.0 ± 19.9 2.5 ± 0.4 12.0 ± 1.8
bezafibrate 22.5 ± 5.0 129.0 ± 5.1 92.2 ± 25.2 175.3 ± 12.6
gemfibrozil 27.5 ± 9.6 137.0 ± 25.6 93.1 ± 30.9 180.4 ± 18.9
WY-14643 10.0 ± 0.0 139.0 ± 8.2 82.4 ± 20.2 141.0 ± 3.8
HepG2 fenofibtrate 20.0 ± 0.0 117.0 ± 7.0 76.1 ± 4.7 188.0 ± 8.5
bezafibrate 23.3 ± 23.1 139.0 ± 42.6 200.0 ± 8.8 332.3 ± 16.1
gemfibrozil 10.0 ± 0.0 127.0 ± 10.4 251.3 ± 25.7 350.0 ± 13.3
WY-14643 76.7 ± 5.8 173.0 ± 20.0 121.9 ± 26.2 265.1 ± 20.1
HT-29 fenofibtrate 13.3 ± 5.8 137.0 ± 10.3 205.7 ± 4.0 327.0 ± 38.0
bezafibrate 10.0 ± 0.0 141.0 ± 14.4 201.1 ± 27.7 268.8 ± 27.1
gemfibrozil 76.7 ± 5.8 145.0 ± 14.4 191.6 ± 37.6 261.2 ± 36.8
WY-14643 63.3 ± 11.5 147.0 ± 21.3 184.0 ± 20.8 263.5 ± 15.3
Table presents summary of detected concentration which promotes viability of the cells (max. viability - concentration) and relative viability of the cells reached in
these concentration (max. viability - relative viability as a % of viability of the control cells). IC10 and IC50 concentrations of tested fibrates for estimated cell lines
are also displayed. Data are presented as average concentration of fibrate ± SD (n = 3)
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samples in comparison to control cells were counted as
following:
fold change ¼ average % of positive cells in treated sample
average % of positive cells in control sample
These results are shown in graphs as fold change on
log 2 scale. Data were also evaluated by Student’s t-test
at the p < 0.05 level of significance. All calculations were
performed using MS Excel 2010. Statistically significant
results are marked with asterisk (*).
Cell cycle analysis
Cells were plated at 6 cm cultivation dish at density of
2x105 cells/dish for HEK2593 and 4x105 cells/dish for
HepG2, and HT-29 in appropriate growth medium. Cells
were incubated overnight and then treated by fenofi-
brate, bezafibrate, and gemfibrozil in maximal viability
concentrations and IC10. Cells were incubated 24 h in
presence of tested ligands (37 °C, 5 % CO2). As a
control, the cells treated by 0.1 % DMSO were used.
Following trypsinization, cells were washed in PBS and
centrifuged at 2000 rpm for 10 min. Then, supernatants
were removed and cells were fixed by ice cold 70 % eta-
nol for 30 min on ice. Fixed cells were washed by 0.1 %
sodium citrate and centrifuged at 2500 rpm for 5 min.
Supernatants were removed and propidium iodide solu-
tion (100 μg/1 ml) was added (600 μl of PI per sample),
cells were incubated 15 min at 37 °C. Then, 400 μl of
RNase per sample were added and incubated again for
15 min at 37 °C. Before measurement, cells were left at
least for 30 min on ice. Cells were analyzed for cell cycle
using flow cytometer BD FACSVerse (BD, USA) which
provided histograms to evaluate cell cycle distribution.
Results
Viability of HEK293, HepG2, and HT-29 cells after
treatment by various PPARα ligands
We investigated effects of 4 different PPARα ligands
(fenofibrate, bezafibrate, gemfibrozil, WY-14643) on
viability of HEK293, HepG2 and HT-29 cell lines. We
determined IC50 and IC10 concentrations for all investi-
gated ligands. Moreover, at lower concentrations of the
ligands, an increase of proliferation in all tested cell lines
was apparent for all tested ligands. Hence, we determi-
nated concentrations of ligands when cell viability was
maximal. Relative viability of cells in a concentration of
maximal viability vary from 117 to 173 % of control. All
these results (IC50, IC10, and maximal viability concen-
tration) for all three cell lines are summarized in Table 1.
To confirm that DMSO treatmen does not significantly
affect cell viability, cells were treated by 0.1 and 1 %
DMSO. For results, see Additional file 2.
Because of fenofibrate, bezafibrate, and gemfibrozil
widen clinical utilization, we defined cell viability at 3
different concentrations in range of therapeutic plasma
concentrations of these drugs which is reached in patient
plasma after normal dosing of these drugs. The thera-
peutic doses and plasma concentrations of these drugs
and relative viability of tested cell lines after treat-
ment are summarized in Fig. 1. All three ligands, with
exception of fenofibrate in HEK293 cell lines, showed
an increase of proliferation in these ranges of concen-
trations in comparison to control cells. Statistically
Fig. 1 Viability of cells in concentration range which is reached in patients plasma after therapeutic dose of fibrates. Viability of tested cell lines is
predominantly incerased after treatment by fibrates in a range of concentration which is reached in patient plasma after normal dosing. *
Statistically different from control value at p < 0.05
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significant results are marked by * (p < 0.05), for P
values, see Additional file 3.
To confirm increased proliferation after the fenofi-
brate, bezafibrate, and gemfibrozil treatment, we used
immunocytochemical detection of proliferation marker
Ki-67. Ki-67 is a nuclear protein associated with cellular
proliferation and it is expressed independently on spe-
cific phase of cell cycle (G1, S, G2, M). All cell lines were
treated by maximal viability concentrations of fibrates
determined by WST-1 test. Ratio of Ki-67 positive cells
were increased after fibrates treatment (Table 2 and
Fig. 2, part A) as fold change. These result confirmed in-
creased proliferation detected by WST-1 test.
Changes in subcellular localization of PPARα
To confirm that an increase in proliferation and changes
in expression of cell cycle regulators could be PPARα-
dependent, we investigated presence and subcellular dis-
tribution of PPARα. We detected both, cytoplasmic and
nuclear localization of PPARα. In all three tested cell
lines we detected an increased number of cells with nu-
clear positivity of PPARα in comparison to control cells.
The results are shown in Fig. 2, part B as fold change.
Changes in ratio of cells expressing cell cycle regulation
proteins
To investigate why cell proliferation is increased after
the treatment with fibrates, we used immunocytochem-
istry for detection of cell cycle regulation protein expres-
sion, namely cyclin E, cyclin A, Cdc25A in control cells
(treated by 0.1 % DMSO) and cells treated by maximal
viability concentration and IC10 of fibrates determinated
by WST-1. The expression of all tested proteins was de-
tected in all tested cell lines.
Cyclin E, cyclin A, and Cdc25A are regulators of late
G1 and S phase of the cell cycle. Results for all tested
cell lines are summarized in Table 2. Changes in expres-
sion of theese proteins are shown in Fig. 2, part C, D, E
as fold change. Statistically significant changes are labed
by *, for P values, see Additional file 4. Briefly, increased
number of cells expressing cyclin E in all tested cll lines
was detected. Moreover, number of cells expressing cyc-
lin A was increased in carcinoma cell lines (HepG2, HT-
29). Cdc25A is downregulated in all tested cell lines. All
these changes are concentration-dependent.
Confirmation of p53 presence
We also confirmed presence of p53 in all tested cell
lines. In all three tested cell lines, the majority of cells
were positive for this protein. We detected both, cyto-
plasmic and nuclear positivity. Results of immunohisto-
chemistry staining and ratio of positive cells (displayed
as average ± SD) after treatment by 0.1 % DMSO are
shown in Fig. 3.
Western blot analysis of CYP2J2 expression
We hypothetized if observed changes in cell viability are
connected with changes of expression of CYP2J2.
CYP2J2 were detected in all tested cell lines. We de-
tected obvious increase in CYP2J2 expression after treat-
ment in proliferation concentrations. The cells treated
with IC10 concentrations showed return to CYP2J2 ex-
pression to level comparable to control cells or slight
downregulation. Only one exception is remaining of
higher expression of CYP2J2 in HepG2 cell line after
Table 2 Ratio of Ki-67, cyclin E, cyclin A, and Cdc25A positive cells in tested cell lines obtained by immunocytochemistry
antigen Ki-67 cyclin E cyclin A Cdc25A














HEK293 control 73.44 ± 6.39 56.82 ± 9.68 55.19 ± 4.00 57.25 ± 9.14
fenofibrate 95.04 ± 7.49 82.11 ± 3.58 73.39 ± 9.26 44.99 ± 0.62 53.49 ± 5.40 37.04 ± 7.65 22.82 ± 8.84
bezafibrate 91.31 ± 6.83 77.95 ± 2.39 70.33 ± 8.29 46.35 ± 0.05 56.41 ± 0,42 40.23 ± 4.80 22.79 ± 10.74
gemfibrozil 98.82 ± 0.45 74.42 ± 2.46 62.89 ± 2.15 46.98 ± 2.30 49.83 ± 5.31 47.03 ± 2.94 23.79 ± 7.75
HepG2 control 77.59 ± 1.81 46.65 ± 7.69 34.22 ± 6.06 48.70 ± 6.71
fenofibrate 83.14 ± 7.05 65.67 ± 3.35 65.21 ± 29.03 42.55 ± 2.23 33.08 ± 3.49 44.92 ± 5.65 40.56 ± 6.81
bezafibrate 80.82 ± 5.77 59.60 ± 2.33 62.2 ± 8.86 41.59 ± 0.23 38.09 ± 12.48 40.45 ± 5.12 23.92 ± 7.96
gemfibrozil 82.39 ± 5.54 55.08 ± 2.31 61.57 ± 3.08 47.04 ± 3.72 45.43 ± 4.03 39.94 ± 9.19 24.63 ± 7.98
HT-29 control 72.83 ± 4.33 15.69 ± 1.39 18.39 ± 2.82 57.66 ± 9.41
fenofibrate 85.96 ± 5.09 24.07 ± 1.02 44.34 ± 6.62 20.36 ± 2.53 59.45 ± 13.84 39.53 ± 4.00 10.60 ± 9.70
bezafibrate 94.37 ± 1.07 21.64 ± 2.04 39.38 ± 12.53 19.53 ± 1.32 53.23 ± 6.14 43.77 ± 8.44 35.88 ± 8.40
gemfibrozil 90.59 ± 0.88 23.02 ± 2.25 42.64 ± 11.07 18.65 ± 1.13 38.70 ± 21.33 51.13 ± 6.97 46.26 ± 4.32
We evaluated % of positive cells in 3 different fields of vision for these antigens in control and fibrates treated HEK293, HepG2, and HT-29 cell lines. Cells were
treated by maximal viability and IC10 concentrations of used fibrates. Results are shown as % of positive cells ± SD (n = 3)
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Fig. 2 (See legend on next page.)
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WY-14643 treatment at IC10 concentration. Representa-
tive results are shown in Fig. 4.
Cell cycle analysis
We detected no changes in distribution of cell cycle
phases after maximal viability treatment in all tested cell
lines in comparison to control cells (treated by 0.1 %
DMSO) for all three tested cell lines. Cells treated by
IC10 concentrations of tested fibrates showed an in-
crease of cells in G1 phase in comparison to control
cells (see Fig. 5). We also detected an increased number
of tetraploid cell in HepG2 cell line after the gemfibrozil
treatment.
Discussion
PPARα is a ligand-activated transcription factor involved
in regulation of lipid and energy metabolism, inflamma-
tion, and xenobiotic metabolism. There are many of
both, exogenous and endogenous compounds which
serve as PPARα ligands. PPARα ligands include fibrates,
phtalates, herbicides, saturated and unsaturated fatty
acids, prostaglandins, leucotriene B4, epoxyeicosatrie-
noic acids (EETs), and etc. [3].
PPARα ligands such as fenofibrate, bezafibrate, and
gemfibrozil are well kown hypolypidemic drugs and
thus, they can improve clinical consequences of meta-
bolic disorders asocciated with increased cancer risk.
They have long history of clinical usage, been shown to
be well tolerated and to have limited side effects and/or
toxicity. Long-term administration of PPARα agonists
causes liver cancer in rodents. However, this effect is not
evident in humans [1]. Moreover, they have been consid-
ered as potential anticancer agents [5–9].
In this study, we investigated effects of a wide range of
concentrations of fenofibrate, bezafibrate, gemfibrozil,
and WY-14643 on viability of three human cell lines:
HEK293, HepG2, and HT-29. Our results shown the
same trend in all estimated cell lines. At lower concen-
tration of all tested fibrates, increased proliferation is ob-
served, whereas at higher concentration, repression is
apparent. Increased viability of all cell lines treated by
lower concentrations of fibrates was comfirmed by in-
creased Ki-67 expression in tested cells. Fenofibrate, beza-
fibrate, and gemfibrozil are widely used for dyslipidemia
treatment. Unfortunately, with exception of HEK293 cells
treated by fenofibrate,concentrations of fibrates with a
promotive effect for proliferation are in the range of
concentrations which are reached in patient plasma after
normal therapeutical dosing of these drugs. Our data are
with good agreement with Suchanek et al. They detected
increased proliferation after WY-14643 and clofibrate
treatment in human breast cancer cell lines. The in-
crease in proliferation was more significant in lower
concentration of WY-14643, wherease higher concen-
tration produced only a slight increase in proliferation
of tested cell lines [12].
It has been described a lot of effects of PPARα ligands on
cancer for cancer [4, 10, 13–15, 17]. Animal experiments
provide promising results in field of PPARα-dependent
regulation of CYP epoxygenases and consequent marked
(See figure on previous page.)
Fig. 2 Changes in expression of Ki-67, subcellular localization of PPARα and expression of cell cycle regulators. a Ki-67 is a marker of cell proliferation
which is independent on specific phase of cell cycle (G1, S, G2, M). Increased number of Ki-67 positive cells was detected after treatment at maximal
viability concentrations of used fibrates. These results confirm increased viability after fibrate treatment determined by WST-1 test. b In all three tested
cell lines, we detected an increased number of cells with nuclear positivity of PPARα after fibrates treatment. Both, cytplasmic and nuclear positivity, is
apparent. c Expression of cyclin E is increased in HEK293, HepG2, and HT-29 cell lines after fibrate treatment. d Expression of cyclin A is increased in
carcinoma cell lines HepG2, and HT-29. In HEK293 cell line, there is slight decrease in cells treated by maximal viability concentrations of fibrates.
e Expression of Cdc25A is decreased in HEK293, HepG2, and HT-29 cell lines after fibrate treatment. Graphs display results as fold changes. * Statistically
different from control value at p < 0.05. Microphotographs (magn. 400×) show expression of proteins of interest in control cells (treated by 0.1 % DMSO)
Fig. 3 Expression of p53 in HEK293 (a), HepG2 (b), and HT-29 (c) cell lines. In all tested cell lines, he majority of cells was positive for p53. The p53
protein was predominantly nuclear, cytoplasmic expression was also detected (magn. 400×). Ratio of positive cells is displayed as average ± SD
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reduction of tumour mass volume and vascularization in
mice [17]. CYP epoxygenases (mainly CYP2C and CYP2J
subfamilies) convert arachidonic acid (AA) to four regioi-
somers of EETs. AA is dietary polyunsaturated ω-6 fatty
acid which is part of normal nutrition. EETs are involved in
inflammation, mitogenesis, cell signalling, angiogenesis,
regulation of vascular tone, and ion channels. It has been
described that EETs promote tumour growth by increasing
cell proliferation and apoptosis inhibition [16, 18]. CYP
epoxygenases are significantly expressed in variety of
tumour tissues. These enzymes and their metabolites are
possibly related to the incidence and progression of
tumours [18–20].
In mice, it has been showen that PPARα agonists
downregulate CYP epoxygenases expression. On the
other hand, expression of human CYP2C and CYP2J
mRNAs are upregulated by PPARα ligands [4]. Al-
though the downregulation of CYP2C is apparent also
in PPARα-humanized mice, differences in regulation
of CYP2C in mice and humans could be attributed to
differences in the regulatory regions of the responsive
genes, which have been described for several genes
before [21, 22]. This inter-species differences in
regulation of CYP2C proteins expression should be
considered in evaluation and transfer of rodent study
results to humans.
Our results show that fibrates affect CYP2J2 expression
in dose-dependent manner. CYP2J2 level is increased in
tested cell lines after lower-concentrations fibrates treat-
ment. This increase is probably followed by increase of
cytoprotective EETs concentration in tested cells and
could explain increased viability of the cells.
Fig. 4 Expression of CYP2J2 in HEK293, HepG2, and HT-29 cell lines in control cells and after fibrates treatment in concentration which promotes viability
and IC10. Generally, in maximal viability concentrations, CYP2J2 protein expression is elevated in all tested cell lines. In IC10 concentrations, CYP2J2 is
returned to control levels or slightly downregulated. The higher expression of CYP2J2 could explain increase in viability of the cells. Detection of GAPDH
expression was used as endogenous control. Relative protein expression was evaluated by measuring optical density (OD)
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To support our assumption that these efects are
PPARα-dependent, we estimated presence and subcel-
lular localization of PPARα in tested cell lines in
control and fibrate treated cells. While localization of
PPARα is widely regarded as nuclear, cytoplasmic
localization has also been described [23–25]. We de-
tected both, nuclear and cytoplasmic localization of
PPARα. Cells with nuclear positivity of PPARα were
accumulated after PPARα ligands treatment. Recently,
Umemoto et Fujiki [26] have described dynamic shut-
tle between nucleus and cytoplasm which is regulated
by multiple pathways and nuclear transport of PPARα
is accelerated by its ligands which is in good agree-
ment with our results.
In further experiments, we investigated expression of
cell cycle regulatory proteins after fibrate treatment.
Cell cycle progression is mainly controlled by cyclins
and cyclin-dependent kinases (CDKs). Activities of cyc-
lin/CDKs complexes are regulated on different levels,
such as transcription of their genes, proteolysis, subcel-
lular localization, binding of specific inhibitors, and
reversible phosphorylation [27]. Common feature of all
tested fibrates are changes in expression of Cdc25A
and cyclin E in all three tested cell lines and cyclin A in
carcinoma-derivated cell lines HepG2 and HT-29.
These effects are concentration-dependent. Cyclin E
and cyclin A are regulators of late G1 and S phases of
cell cycle. Both cyclins make complex with cyclin-
dependent kinase 2 (CDK2). For activation of these
complexes, dephosphorylation of CDK2 by Cdc25A is
needed. All together, these proteins induce progression
from G1 to S phase of cell cycle. Overexpression of
Cdc25A phosphatase is often observed in cancer and
results in poor prognosis. Downregulation of Cdc25A
could play a role in the prevention of uncontrolled cell
growth as long as p53 is intact [27]. In maximal viabil-
ity concentrations, Cdc25A downregulation seems to
be insufficient for cell cycle arresting and together with
upregulation of cyclin E (and cyclin A), fibrates pro-
mote cell proliferation. Sufficient downregulation of
Cdc25A for arrest of cell cycle is probably reached in
IC10.
Fig. 5 Results of cell cycle analysis. There is an accumulation of cells in G1 phase after fibrate treatment in IC10 concentration
Cizkova et al. Lipids in Health and Disease  (2016) 15:164 Page 9 of 11
Conclusion
According to information mentioned above, it seems
that PPARα is not pure oncogene or tumour suppressor.
Althought many of anticancer effects of fibrates are
described in literature, based on our research, we sug-
gested there is no anti-cancer effect of fibrates in tested
carcinoma cell lines. The increased proliferation of the
cells are accompanied by the induction of CYP2J2
protein which could explain this phenomenon. Because
of widen clinical utilization of fibrates, their effect on
cell viability needs further investigation and their usage
should be considered carefully.
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